16 completed. 16 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 16 |
Follow Prevnar 13™: new trials by email Literature Review of Prevnar 13™ trials Research Report on Prevnar 13™
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033) V114, PCV13 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 694 | 2020-07-01 | 2023-07-28 |
| Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 407 | 2019-11-05 | 2023-06-07 |
| Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026) V114, Prevenar 13™, Vaxelis™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1191 | 2019-08-28 | 2023-05-06 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020) V114, Prevnar 13™ - Pneumococcal Infections, Pneumonia, Pneumococcal | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2340 | 2019-06-12 | 2021-04-12 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE) V114, Prevnar 13™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 104 | 2019-01-23 | 2021-06-16 |
| A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK) V114, Prevnar 13™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2409 | 2018-12-14 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 277 | 2018-09-12 | 2023-07-28 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1515 | 2018-07-16 | 2021-01-15 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 302 | 2018-07-06 | 2022-05-05 |
| A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH) V114, Prevnar 13™, PNEUMOVAX™23 - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 652 | 2018-06-22 | 2021-11-02 |
| Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029) Prevnar 13™, Pneumovax™ 23, Placebo - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 400 | 2014-08-28 | 2021-11-02 |
| A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) V419, PENTACEL™, Prevnar 13™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2808 | 2011-05-10 | 2018-11-15 |
| Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) V419, DAPTACEL™, PedvaxHIB™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1473 | 2011-04-19 | 2018-11-15 |
| Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108), ActHIB™, Pentacel™ - Haemophilus Influenzae Type b | Phase 3 | Completed | GlaxoSmithKline | 4003 | 2010-06-18 | 2018-07-12 |
Pneumococcal Infections (13) · Haemophilus Infections (3) · Bacterial Infections (2) · Diphtheria (2) · Hepatitis B (2) · Poliomyelitis (2) · Tetanus (2) · Virus Diseases (2) · Whooping Cough (2) · Gram-Negative Bacterial Infections (1) · Pneumonia, Pneumococcal (1)
Merck Sharp & Dohme LLC (15) · GlaxoSmithKline (1)
United States (10) · Thailand (5) · Australia (4) · Canada (3) · Finland (3) · Brazil (2) · Chile (2) · Colombia (2) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Peru (2) · Puerto Rico (2) · South Africa (2)
PMID 27846058, PMID 34019468, PMID 34489128, PMID 34750291, PMID 35039194, PMID 35146039, PMID 36383730, PMID 36522265, PMID 36621410, PMID 36841723, PMID 36939067, PMID 37309607, PMID 37338158, PMID 37344262, PMID 37846456, PMID 40537903
2018 (7), 2017 (3), 2019 (2)